The self-administration model is the primary non-clinical approach for assessing the reinforcing properties of novel compounds. Given the now frequent use of rats in self-administration studies, it is important to understand the predictive validity of the rat self-administration model for use in abuse liability assessments. This review of 71 drugs identifies high concordance between findings from rat self-administration studies and two clinical indicators of abuse liability, namely reports of positive subjective-effects and the DEA drug scheduling status. To understand the influence of species on concordance we compare rodent and non-human primate (NHP) self-administration data. In the few instances where discrepancies are observed between rat data and the clinical indicators of abuse liability, rat self-administration data corresponds with NHP data in the majority of these cases. We discuss the influence of genetic factors (sex and strain), food deprivation state and the study design (acquisition or drug substitution) on self-administration study outcomes and highlight opportunities to improve the predictive validity of the self-administration model.
4.2.
Genetic factors (strain and sex 
Introduction
Understanding the abuse liability of novel compounds acting in the central nervous system (CNS) is an important part of the drug development process and is essential from a public health perspective. Abuse liability is often defined as the potential for repeated taking of a drug for its reinforcing or subjective-effects, or the avoidance of associated negative effects. A variety of factors such as the drug formulation, its ease of synthesis, cost and the social acceptability of drug taking can also influence the likelihood of abuse liability (Katz and Goldberg, 1988) . The task of assessing abuse liability therefore requires a broad range of both clinical and non-clinical models that can measure each of the distinct factors that contribute to risk of abuse. These models are referred to as models of abuse potential .
Non-clinical animal models of abuse potential, which include drug self-administration, drug discrimination, physical dependence and withdrawal and conditioned place preference, offer a particularly valuable approach for predicting abuse liability (see Ator and Griffiths, 2003; Carter and Griffiths, 2009; Sanchis-Segura and Spanagel, 2006; Tzschentke, 1998 for review) . Critically, these models can be used early on in the drug development process to identify candidate drugs that may offer a reduced risk of abuse liability over clinically available therapies. Further, findings from animal models of abuse potential are required for the regulatory approval of centrally active drugs and to determine their scheduling status, since these models permit testing of conditions not possible or ethical in humans (EMEA, 2006; FDA, 2010; Health Canada, 2006; Spillane and McAllister, 2003) . Given the importance of animal models of abuse potential for drug development, it is imperative that the predictive validity of each model for abuse liability is understood. With this knowledge, the predicative limitations and key experimental variables of the models can be recognised and opportunities to improve the predictive validity of the models can be identified.
In the drug self-administration model, animals are required to elicit a response (such as a lever press) in order to obtain drug (Clark et al., 1961; Weeks, 1962) . This model is therefore used to examine the reinforcing properties of a drug (that is, the ability of a drug to increase the subsequent probability of a response that precedes its delivery), which is a key factor that influences the risk of abuse liability (Balster and Bigelow, 2003; Johanson, 1990; Panlilio and Goldberg, 2007) . Previous reviewers have found high predictive validity of the self-administration model for abuse liability when conducted in non-human primates (NHPs) (Griffiths and Balster, 1979; Johanson and Balster, 1978) . In addition, experimental variables that can influence the outcome of NHP self-administration studies have been well described Brady and Griffiths, 1976; Deneau et al., 1969; Schuster and Thompson, 1969; Woolverton and Nader, 1990) .
In recent decades, methods for using rats in self-administration studies have been advanced (Caine et al., 1993) and rat selfadministration studies are now used extensively for both basic drug addiction research (for example, Deroche-Gamonet et al., 2004) and in assessments of abuse potential (for example, Haney and Spealman, 2008) . However, limited data is publically available concerning the predictive validity of the self-administration model conducted in rats for assessing abuse liability, even though the choice of species used may be a key experimental variable that influences the outcome of self-administration studies Schuster and Thompson, 1969) . This review therefore provides an overview of findings from self-administration studies conducted using rats in order to determine the predictive validity of this model for understanding risk of abuse liability.
Methodological issues
A drugs propensity for abuse liability is dependent on a multitude of social, economic and biological factors (Katz and Goldberg, 1988) . Unsurprisingly, there exists no all-encompassing clinical measure of 'abuse liability' and it must be considered as an abstract term that can only be measured by the observation of more readily identifiable endpoints. Nevertheless, in order to understand the predictive validity of the rat self-administration model for abuse liability, it is necessary to identify appropriate clinical indicators of abuse liability against which the predictive validity of the model can be assessed. In the present review, two clinical indicators of abuse liability are employed, namely reports of positive subjective-effects (that is, reports of drug 'liking', 'euphoria' and/or 'high') measured in controlled clinical studies, and the Drug Enforcement Agency (DEA) drug scheduling status.
Clinical indicators of abuse liability

Reports of positive subjective-effects
The first clinical indicator of abuse liability was chosen based on its ability to measure drug reinforcement in humans. In theory, this indicator would provide the most direct comparison to findings from non-clinical drug self-administration studies (Stephens et al., 2010) . Clinical studies considered to measure drug reinforcement include those of subjective-effects, self-administration and drug choice (Fischman, 1989; Henningfield et al., 1991; Jasinski, 1977; Johanson and de Wit, 1989) . In constructing this review, studies of subjective-effects were found to be more widely and consistently used between different laboratories than either clinical self-administration studies or studies of drug choice.
In studies of subjective-effects, human volunteers who have typically had prior illicit drug experience (as recreational or drug dependent users) are dosed with the test substance and recordings of subjective-effects are made at various intervals post-dosing (see Carter and Griffiths, 2009 for further details). A number of instruments have been used to measure subjective drug effects, including the Visual Analogue Scales (VAS) of global drug effects, the Single Dose Questionnaire (Fraser et al., 1961) and the Addiction Research Centre Inventory (Haertzen, 1966) . These scales have been reviewed extensively elsewhere Jasinski and Henningfield, 1989) . Essentially, the scales address one or more of four key concepts:
1. Whether a subject feels a drug effect (drug feeling). 2. Whether a subject can indicate the drug class most similar to the test drug (drug class). 3. Identification of sensations the subject is experiencing (drug symptoms). 4. Whether the subject likes the drug (drug liking).
Reports of subjective-effects are generally recognised as being highly indicative of abuse liability Jasinski, 1977; and reports of 'drug liking' have been found to correlate well with findings from NHP selfadministration studies (Griffiths and Balster, 1979; Schuster and Thompson, 1969) . For these reasons, reports of positive subjectiveeffects (that is, drug 'liking', 'euphoria' and/or 'high') were used in the present review to address the predictive validity of the rat self-administration model for abuse liability.
Drug scheduling status
In the United States of America, the process for drug scheduling typically requires the Food and Drug Administration (FDA) to complete a medical and scientific assessment of the risk for abuse on behalf of the Department for Health and Human Services (HHS), incorporating input from the National Institute on Drug Abuse (NIDA), and to make a recommendation to the DEA for the appropriate scheduling status. The Controlled Substances Act (CSA) of 1970 details the legislative control requirements for substances of abuse. According to the Act, substances may be placed into one of five schedules (I-V) based upon the substance's medical use, potential for abuse and safety or dependence liability (see Spillane and McAllister, 2003 for review) . Schedule I drugs are those with recognised abuse liability, but no currently accepted medical use (for example, lysergic acid diethylamide (LSD)), while substances in schedules II-V are FDA approved compounds placed according to their relative propensity for abuse or for the development of physical or psychological dependence. Thus, schedule III drugs are considered to possess lower risk for abuse than schedule II drugs, and so on. To determine whether a substance should be scheduled, and if so, into which schedule it should be placed, the CSA details an 'eight factor analysis' of abuse liability which considers:
1. The drug's actual or relative potential for abuse. 2. Scientific evidence of the drug's pharmacological effects. 3. The state of current scientific knowledge regarding the substance. 4. Its history and current pattern of abuse. 5. The scope, duration, and significance of abuse. 6. What, if any, risk there is to the public health. 7. The drug's psychic or physiological dependence liability. 8. Whether the substance is an immediate precursor of a substance already controlled.
The broad scope of the eight-factor analysis suggested that scheduling status could offer a more comprehensive indication of 'real-world' abuse liability than reports of positive subjectiveeffects alone. Thus, drug scheduling status, obtained from the DEA drug scheduling list of The United States Department of Justice (U.S. Department of Justice, D.E.A., 2009) was included as the second clinical indicator of abuse liability.
Categorisation of study findings
Experimental methodologies and reporting practices vary considerably, not only between non-clinical self-administration studies and clinical studies of subjective-effects, but also within the respective non-clinical and clinical literature.
In the animal drug self-administration literature, rates of responding on an operant (for example, a lever) that leads to delivery of the test drug (termed the 'active' lever) are typically reported. In most cases, a second operant is also present on which responding has no scheduled consequence (termed the 'inactive lever'). Whether a test drug maintains self-administration can therefore be determined by the statistical comparison of group mean active and inactive lever response rates, or between infusion rates maintained by various doses of the test drug and a negative control (typically the vehicle of the test drug). Thus, the presence of selfadministration is identified as responding for the test drug which significantly exceeds responding for the negative control at one or more doses of the test drug examined. In studies where no negative control is included, self-administration is identified as responding for the test drug which significantly varies as a function of dose and/or by responding selectively on the active lever over the inactive lever. In some reports, individual animal data is reported, such that the proportion of animals which self-administer the test drug can be described.
Clinical studies employ a variety of rating scales to measure positive subjective-effects (as discussed in Section 2.1.1). Thus, subjects may score on a continuous scale the extent to which they 'like' the drug effect (for example, 0: dislike a lot; 50: neutral; and 100: like a lot) and statistical comparisons are then made between group mean rating scores following administration of the test drug and a placebo control. In some studies, individual data are reported such that the proportion of subjects who reported positive subjectiveeffects can be described.
To facilitate the comparison of findings between and amongst non-clinical and clinical studies in the present review, findings from animal self-administration studies and clinical studies of positive subjective-effects are classified as positive (+), equivocal (+/−) or negative (−). Positive findings are defined as those in which statistically significant reports of self-administration or positive subjective-effects (that is, 'drug liking', 'euphoria' and/or 'high') were described or, for studies where individual data were reported, where self-administration or positive subjective-effects were reported in >50% of the experimental cohort. Equivocal findings are defined as those in which self-administration or positive subjective-effects were reported in at least one, but ≤50% of the experimental cohort. Negative findings are defined as those in which no evidence of self-administration or positive subjective-effects were found, as demonstrated by a lack of statistical significance in group mean data, or the absence of positive findings in any of the experimental cohort.
Inclusion and constraint criteria
A literature search using MEDLINE (1950-date) , EMBASE (1974-date) , PUBMED, the Derwent Drug File (1983-date) and Biosis Previews (1969-date) was performed to identify drugs that were assessed in the rat self-administration model and which could be compared with at least one of the chosen clinical indicators of abuse liability. For drugs that met this initial criterion, database searches were used to identify equivalent reports of self-administration conducted in NHPs. By contrasting rodent and NHP self-administration data, we sought to further understand the influence of species in determining the predictive validity of the self-administration model (see Section 4.1).
A number of additional inclusion and constraint criteria are applied in order to provide a more useful and relevant database. First, only self-administration studies that delivered drugs in ways considered reflective of common clinical routes of administration (that is, intravenous, oral and inhalation) are included. Second, studies where data from only one subject was reported are excluded. Third, findings from studies that examined compounds in combination (for example, cocaine and heroin as a 'speedball', or hashish) are excluded. Fourth, this review does not intend to offer a complete bibliography of rat self-administration studies. Thus, for drugs where self-administration in rats has been extensively reported (for example, cocaine and nicotine) we include only a representative sample of studies that encompass a variety of study designs.
The predictive validity of the rat self-administration model for abuse liability
The present review identified 71 drugs that were assessed in the rat self-administration model and could be contrasted with findings from either clinical studies of subjective-effects and/or drug scheduling status for the purpose of understanding the predictive validity of the rat self-administration model for abuse liability (see summary tables; Tables 1-4). No published reports measuring subjective-effects were available for 17 drug cases and no evidence of consideration for drug scheduling was available for ketocyclazocine.
Findings from rat self-administration studies were concordant with at least one clinical indicator of abuse liability in 64 of 71 (90.1%) drug cases. That is, positive reports of self-administration for a particular drug corresponded with either reports of positive subjective-effects and/or a drug scheduling status for the drug, and vice-versa. When comparing findings from rat self-administration studies independently with each clinical indicator of abuse liability, findings from rat studies were concordant with reports of positive subjective-effects in 41 of 54 (75.9%) drug cases and were concordant with drug scheduling status in 49 of 70 (70%) cases.
The following section summarizes the findings of this review, while a complete set of references is provided in the summary tables. In addition to detailing whether drugs were self-administered in animals, produced reports of positive subjective-effects in humans and/or were listed as controlled substances, the summary tables also detail the primary pharmacological action of each drug, the strain of rat (or NHP species) used, the class of training drug (if any) the animal was trained to selfadminister prior to the test drug and the dominant drug experience (if any) of human volunteers used for studies of subjective-effects.
Opioid drugs (Table 1)
Self-administration in rats was maintained by the -opioid agonists codeine, diamorphine (heroin), dihydroetorphine, etonitazine, fentanyl, hydrocodone, levo-alphacetylmethadol (LAAM), meperidine, methadone, morphine, oxycodone, propoxyphen, remifentanil and sufentanil. These findings corresponded with reports of positive subjective-effects in humans and/or recognised scheduled status, typically schedule I-II (see Table 1 for references).
The atypical opioid analgesic tramadol was self-administered in rats (O'Connor and Mead, 2010) but is not a controlled substance and did not consistently engender reports of positive subjectiveeffects (Cami et al., 1994; Zacny, 2005) . This discrepancy may be resolved, in part, by consideration of the complex metabolic profile of tramadol (see O'Connor and Mead, 2010 for discussion). Further, the use of a more complex reinforcement schedule in rats and NHPs identified tramadol as a relatively weak reinforcer relative to typical analgesics with recognised abuse liability Yanagita, 1978) . These findings are entirely consistent with the low risk of tramadol abuse liability in humans (Epstein et al., 2006) .
The -opioid antagonist levallorphan and the non-selective opioid antagonist naloxone did not support self-administration in rats (Collins et al., 1984; Nishida et al., 1989) . Although neither drug is scheduled, levallorphan did produce increases in 'liking' in human volunteers, as measured using a single-dose opiate questionnaire. However, overall changes in subjective-effects following levallorphan treatment were considered quite distinct from those of other narcotic analgesics (Jasinski et al., 1967) , highlighting a limitation of using solely reports of positive subjective-effects as a clinical indicator of abuse liability.
For drugs acting at both -and -opioid receptors, selfadministration in rats was reported for butorphanol, nalbuphine, and pentazocine (Nishida et al., 1989; Steinfels et al., 1982) . These drugs also produced positive subjective-effects in humans (Mello et al., 2005; Walsh et al., 2001; Zacny et al., 1997 Zacny et al., , 1998 , but were assigned with a lower scheduling status than the aforementioned -agonists (typically schedule III-IV). The -partial agonist/-antagonist nalorphine maintained self-administration in 1 out of 14 rats in one report (van Ree et al., 1978) but was later reported to maintain robust self-administration in rats (Collins et al., 1984) . In humans, nalorphine produced reports of 'liking' (Jasinski et al., 1967) and is a controlled substance (schedule III). Cyclazocine, a -agonist/-antagonist, was not self-administered by rats (Collins et al., 1984; Lahti and Collins, 1982) and is not listed as a controlled substance. In clinical studies, subjects typically reported dysphoric effects following cyclazocine administration, although a few subjects (notably those with a preference for cocaine and/or hallucinogens) reported positive subjective-effects (Haertzen, 1970; Kumor et al., 1986) . Finally, the -and -opioid receptor agonist ketocyclazocine was self-administered in rats (Young and Khazan, 1983) while clinically, Kumor et al. (1986) reported that subjects with a history of drug abuse generally demonstrated a strong dislike for ketocyclazocine. However, a subset of subjects did express a liking for the drug, which similarly for cyclazocine, may reflect their individual drug taking histories (Haertzen, 1970; Kumor et al., 1986) .
In summary, the current review identified 23 opioid related drugs that had been assessed in the rat self-administration model and which could be contrasted with reports of positive subjectiveeffects in humans and/or drug scheduling status. The large volume of literature on the self-administration of opioids in rats together with the high concordance of findings between non-clinical studies and the clinical endpoints of abuse liability provides strong support for the use of the rat model for assessing the abuse liability of opioids. (Table 2) 3.2.1. Dopaminergic drugs Thirteen dopaminergic drugs were included in this review whose function could broadly be categorised into inhibitors of dopamine transporters (DAT), dopamine releasing agents or agonists/antagonists at dopamine receptors.
Monoaminergic drugs
Self-administration in rats was maintained by all DAT inhibitors included in this review (bupropion, cocaine, methylphenidate and nomifensine) and the dopamine reuptake inhibitor, phenmetrazine. Of these drugs, only cocaine, methylphenidate and phenmetrazine reliably produced reports of positive subjectiveeffects in humans and are controlled substances (see Table 2 for references). In contrast, bupropion and nomifensine do not possess significant abuse liability, as confirmed by clinical reports of subjective-effects and their lack of scheduling status Hamilton et al., 1983; Miller and Griffith, 1983; Taeuber et al., 1979) . The discrepancies between the non-clinical and clinical data for bupropion and nomifensine are not yet fully understood, but may reflect adverse events associated with high levels of drug exposure that limit the potential for abuse in humans, but which are not relevant in the animal model (see Section 5.2 for further discussion). Other abbreviations: f, female; m, male; ND, no data; US, not scheduled. +, drug maintains self-administration in animals or reports of positive-subjective effect in humans; +/−, drug maintains equivocal self-administration or reports of positive subjective effect; −, drug does not maintain self-administration or reports of positive subjective effect. 
IV
Of the remaining eight dopaminergic drugs, self-administration in rats was maintained by the dopamine releasers d-amphetamine, diethypropion, cathinone and methylamphetamine, which corresponded with reports of positive subjective-effects in humans and scheduling status (schedule I-IV; see Table 2 for references). The mixed dopamine receptor agonists apomorphine, bromocriptine were self-administered in rats (Wise et al., 1990; Yokel and Wise, 1978 ) but bromocriptine did not produce reports of positive subjective-effects in human participants (Preston et al., 1992a ) and neither drug is listed as a controlled substance. These discrepancies may reflect negative side effects associated with apomorphine and bromocriptine use in humans, thus limiting their potential for abuse (see Section 5.2 for discussion). Interestingly, the mixed dopamine receptor agonist phentermine was self-administered in rats, but only under conditions of food deprivation (Papasava et al., 1985) . Clinically, phentermine produced reports of positive subjective-effects (Brauer et al., 1996) and is listed as a controlled substance. Finally, the dopamine receptor antagonist haloperidol supported the acquisition of self-administration in drug-naïve rats (Glick and Cox, 1975) . This report is surprising given the lack of haloperidol abuse liability, and contrasts with a later negative finding reported in rats under similar experimental conditions (Collins et al., 1984) , suggesting that further studies are required to fully understand the behavioural effects of haloperidol in the rat selfadministration model.
Adrenergic drugs
The noradrenergic transporter (NET) inhibitor imipramine and the NET inhibitor/noradrenergic receptor agonist phenylpropanolamine produced only equivocal reports of selfadministration in rodents (Collins et al., 1984; Wellman et al., 1989) . These drugs did not engender reports of positive subjectiveeffects in human participants (Chait et al., 1987; Frewer and Lader, 1993) and are not listed as controlled substances.
In contrast to findings for NET inhibitors, the adrenergic receptor agonists clonidine and ephedrine readily supported the acquisition of self-administration in drug-naïve rats (Park et al., 2000; Shearman et al., 1981) , although ephedrine was not selfadministered by rats trained to self-administer cocaine (Briscoe et al., 1998) . Both clonidine and ephedrine did not consistently produce reports of positive subjective-effects in humans (Chait, 1994; Cone et al., 1988; Martin et al., 1971 ) and neither drug is listed as a controlled substance.
Serotonergic drugs
The serotonin (5-HT) releasers 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA), and the 5HT-2A agonist mescaline supported selfadministration in rats and produced reports of positive subjective-effects in humans (see Table 2 for references). Both MDA and MDMA are controlled substances (schedule I). In contrast, the 5HT-2B agonist fenfluramine was not self-administered in rats (Gotestam and Andersson, 1975; Papasava et al., 1985) and did not produce reports of positive subjective-effects (Brauer et al., 1996; Gotestam, 1979) . Fenfluramine is listed as a controlled substance (schedule IV), but this may reflect significant side effects associated with withdrawal from fenfluramine use (Vivero et al., 1998) .
Histaminergic drugs
Of the two histamine (H) 1 receptor antagonists included in this review, tripelennamine was not self-administered in rats (Fuchs and Coper, 1986) and is an unscheduled substance that engendered only equivocal reports of positive subjective-effects in human volunteers (Lange and Jasinski, 1986) . Diphenhydramine supported limited self-administration in rats when delivered intravenously (Jun et al., 2004) , but was not self-administered when rats were given the opportunity to drink a solution containing the drug (Fuchs and Coper, 1986) . These reports highlight the important influence of the drug administration route on self-administration study outcomes (see also Ator and Griffiths, 2003; Schuster and Thompson, 1969; Woolverton and Nader, 1990) . Diphenhydramine is not a controlled substance, although reports of positive subjectiveeffects have been recorded (Jaffe et al., 2004; Mumford et al., 1996; Preston et al., 1992b; Wolf et al., 1989) .
In summary, the present review captured findings from 23 monoaminergic related drugs. While the overall concordance between findings from non-clinical studies and the clinical indicators of abuse liability was high, clear discrepancies were observed for certain mixed dopamine receptor agonists (apomorphine and bromocriptine) and DAT inhibitors (bupropion and nomifensine), with false-positive findings observed in animals for all four drugs suggesting a potential over-sensitivity of this model. The adrenergic drugs tended to produce equivocal findings across the rat self-administration literature, but were largely devoid of abuse liability based solely on the two clinical endpoints used in our current review (but see Martin et al., 1971) . Further studies are required to understand these discrepancies, which may point to important predictive limitations of the self-administration model for abuse liability and/or the need to apply more advanced analysis of the drugs effects in order to improve the predictive validity of the model (for further discussion see Section 5).
GABAergic drugs (Table 3)
Of the 12 GABAergic related drugs included in this review, 11 are listed as controlled substances (schedules II-IV; see Table 3 ). The sole exception is the anaesthetic agent propofol, which maintained self-administration in rats (LeSage et al., 2000) but produced only limited reports of positive subjective-effects in humans (Zacny et al., 1993) . However, recent reviewers have called for regulation of propofol as a controlled substance due to accumulating evidence demonstrating clinical abuse of this drug (Wilson et al., 2010) .
Of the barbiturate drugs, amobarbital, methohexital and pentobarbital were self-administered in rats (Collins et al., 1984; Davis, 1968; DeNoble et al., 1985; Pickens et al., 1981; Richardson, 1970) , while phenobarbital self-administration in rats was at best equivocal (Collins et al., 1984; Yoshimura et al., 1984) . The schedule III drug hexobarbital did not support the acquisition of self-administration in drug-naïve rats (Davis, 1968) , however it was self-administered in rats under conditions of unavoidable shock. This study provided early evidence that stress can influence the outcome of self-administration studies (see also Pilotto et al., 1984; Richardson, 1970) .
Of the benzodiazepine drugs, chlordiazepoxide, diazepam, flurazepam and midazolam were self-administered in rats. Diazepam, but not flurazepam, produced reports of positive subjectiveeffects when examined in humans (see Table 3 for references). Falk and Tang (1989a) reported that chlordiazepoxide maintained self-administration in rats that had previously been trained to self-administer ethanol, but was not self-administered in cocaine trained rats, highlighting the importance of the study design in determining study outcome (see Section 4.4 for further discussion).
Gamma-hydroxybutyric acid (GHB), a metabolite of GABA that shows commonality with the behavioural effects of ethanol (Nicholson and Balster, 2001) , maintained self-administration in rats (Colombo et al., 1995 (Colombo et al., , 1998 and produced reports of positive subjective-effects in experienced drug users, but not in non-drug dependent individuals (Carter et al., 2006; Ferrara et al., 1999) .
In summary, the overall agreement between findings from rat studies and the clinical indicators of abuse liability lends support for the use of the rat model in assessing the abuse liability of GABAergic drugs. To some extent, this conclusion is hampered by the relatively few published reports using rodents to examine the reinforcing properties of certain GABAergic drugs. The routine use of rodents for the self-administration of drugs in this class is likely to require further optimization of methodological variables. In particular, the animal's drug history (see Section 4.4 for further discussion) is recognised as an important factor contributing to the reinforcing effects of benzodiazepines (Griffiths and Weerts, 1997; Licata and Rowlett, 2008) .
Cholinergic drugs (Table 4)
The nicotinic-acetylcholinergic receptor agonist nicotine maintained reliable self-administration in rats. In humans, the ability of nicotine administration to produce reports of positive subjectiveeffects depended greatly upon the previous drug experience of participants (Soria et al., 1996 see Table 4 for references). Although abuse of nicotine is widely acknowledged, it is not listed as a controlled substance. The muscarinic-acetylcholinergic receptor antagonist scopolamine and the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline were both selfadministered in rats (Glick, 1982; Rollema et al., 2007) . In non-smoking individuals, varenicline produced a drug high, but this report corresponded with the mean peak report of nausea and was therefore considered unlikely to reflect a positive experience (McColl et al., 2008) . Varenicline and scopolamine are not controlled substances.
While a number of other nicotinic compounds have been assessed in the rat self-administration model, including isoarecolone (Shoaib, 2006) , 5-iodo-A-85380 (Liu et al., 2003) and lobelline (Harrod et al., 2003) , these findings could not be included in the present review due the absence of any comparable clinical data. To fully understand the predictive validity of the rat model for this drug class, it will be of great value to examine the abuse potential of these and other cholinergic related drugs in humans.
In summary, results from the limited database of cholinergic drugs in the rat self-administration model show good concordance with clinical subjective-effects, though relatively poor concordance with drug scheduling status. This is likely due to the fairly unique history of nicotine use and abuse, and its subsequent classification as an unscheduled compound.
Cannabinoid drugs (Table 4)
Self-administration of 9-tetrahydrocannabinol (THC) was reported in rats, but only when animals were food deprived and a fixed-time 1-min non-contingent food delivery schedule was present (Takahashi and Singer, 1979 ) (see also Takahashi and Singer, 1980) . Clinically, THC produced reports of positive subjective-effects in humans (Kelly et al., 1994; Lukas et al., 1995) and THC is a controlled substance (schedule I).
Demonstrating self-administration of THC has proven a difficult task in both rats and NHPs and it is clear that experimental parameters including strain, motivational state, dose and injection speed are critical determinants of success (for thorough reviews see Panagis et al., 2008; Tanda and Goldberg, 2003) . Using a two-bottle choice paradigm in rats, consumption of a solution containing hashish (the major psychoactive constituent of which being THC) was reported to be highly variable in rats (Corcoran and Amit, 1974) . The most convincing evidence of THC self-administration in animals to date has been reported in squirrel monkeys (Justinova et al., 2003; Tanda et al., 2000) . The failure of THC to maintain robust self-administration is likely due to the delayed onset and slow metabolism of THC, but may also simply reflect the relatively weak reinforcing effects of this drug (Maldonado, 2002) . In rats, selfadministration of the synthetic CB1 receptor agonist WIN 55,212-2 has proven more robust (Fattore et al., 2001 ; Lecca et al., 2006) , but further studies using clinically available cannabinoids (for example, nabilone) would be advantageous to fully understand the utility of the rat self-administration model for assessing the abuse liability of drugs in this class.
Glutamatergic drugs (Table 4)
The NMDA antagonists 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine (TCPy), ketamine and phencylcidine (PCP) were self-administered in rats and are controlled substances (schedule I-III) that, when examined in human subjects, produced reports of positive subjective-effects (see Table 4 for references). The mixedaction glutamatergic related drug dextromethorphan was not self-administered in rats, except for when administered in combination with the anti-histamine diphenhydramine (Jun et al., 2004) . Although dextromethorphan is not listed as a controlled substance, it produced reports of positive subjective-effects in humans (Ziaee et al., 2005) . Further, clinical abuse of dextromethorphan for its dissociative effects has been recognised (Mutschler et al., 2010; Romanelli and Smith, 2009 ). Collectively, findings from rat self-administration studies using glutamatergic drugs show broad agreement with the clinical indicators of abuse liability, supporting the use of the rat model for assessing the abuse liability of drugs in this class.
Adenosinergic drugs (Table 4)
The adenosine receptor antagonist caffeine supported only low levels of self-administration in rats and is not a controlled substance. Caffeine reliably produced reports of positive subjective-effects in human volunteers (see Table 4 for references). Clearly, further studies using clinically available adenosinergic drugs (for example, 8-chlorotheophylline) will be of value to thoroughly assess the utility of the self-administration model in abuse liability assessments for drugs in this class.
Steroids (Table 4)
The anabolic-androgenic steroid (AAS) testosterone maintained self-administration in rats (Wood et al., 2004) but did not produce reports of positive subjective-effects in humans (Fingerhood et al., 1997) . Testosterone is a controlled substance (schedule III). The abuse liability of testosterone and other AAS drugs is thought to be influenced by a combination of factors that include psychological dependence due to body image disorders, avoidance of hypogonadism experienced during withdrawal, but also hedonic effects associated with AAS use (Kanayama et al., 2010) . Further studies are required to fully understand the value of the self-administration model in abuse liability assessments of steroids.
Other mechanisms (Table 4)
The antipsychotic chlorpromazine was not self-administered in rats (Collins et al., 1984) and is not a controlled substance. Ethanol maintained self-administration in rats (Grant and Samson, 1985; Lyness and Smith, 1992) and engendered reports of positive subjective-effects (Mintzer et al., 1997) . Although abuse of ethanol is widely acknowledged, it is not listed as a controlled substance. Finally, the anti-narcoleptic and pro-cognitive agent modafinil did not support self-administration in drug-naïve rats (Gold and Balster, 1996) . However, modafinil produced reports of positive subjective-effects in humans (Jasinski, 2000) and is a controlled substance (schedule IV). Reviewers have commented that the lack of widespread modafinil abuse is likely a consequence of its limited solubility in water and chemical instability at high temperatures, thus restricting its potential for abuse via intravenous injection and smoking, respectively (Jasinski and Kovacevic-Ristanovic, 2000) .
Recognising key variables that influence study outcomes
Identifying and understanding discrepancies between nonclinical studies and their clinical counterparts is a critical step for determining the predictive strengths and limitations of a nonclinical model. Moreover, such discrepancies may point to ways of improving the predictive validity of a model. Of the 71 drug cases included in this review, a number of discrepancies were identified between findings from rat self-administration studies and one or both clinical indicators of abuse liability (see Table 5 for summary).
To identify discrepancies, we first classified non-clinical or clinical data sets for a particular drug as representing an overall positive signal when findings from at least one study in the respective data sets were initially categorised as 'equivocal' or 'positive' (for example, rat self-administration data sets for imipramine and flurazepam, and clinical studies for ketocyclazocine and nicotine were all classified as positive signals). Where no reports of self-administration or positive subjective-effects were found for a particular drug, the respective data set was classified as representing an overall negative signal (for example, the rat selfadministration data set for cyclazocine and the clinical data set for fenfluramaine were both classified as negative signals). Nonclinical and clinical data set classifications were then compared for each drug and discrepancies categorised into those representing false positives (that is, a positive signal from self-administration studies in rats but a negative signal from studies of positive subjective-effects and/or scheduling status -a Type I error) or false negatives (that is, a lack of self-administration in rats, but a positive signal from studies of subjective-effects and/or scheduling status -a Type II error). In taking this approach, seven drug cases were identified where findings from rodent studies were considered at odds with both reports of positive subjective-effects and the drug scheduling status (see Table 5 , 'Both clinical endpoints'). A further six cases were identified where rat data were at variance only with reports of positive subjective-effects (see Table 5 , 'Positive subjective-effects only'), and 14 cases were identified where rat data were at variance only with the drug scheduling status (see Table 5 , 'Drug scheduling status only').
In the following sections we further consider these discrepancies in the context of recognising key variables that can influence the outcome of self-administration studies and identifying potential areas of research that may improve the predictive validity of the self-administration model. It must be recognised that for some discrepancies, limited published data precludes conclusive explanations being made and, at best, we can only speculate as to the underlying reasons. Secondly, large variation in the methodologies between studies included in our current review prohibits a more in-depth analysis of the contribution of certain variables (such as rat strain, sex or food deprivation state) to the outcome of self-administration studies. In these instances, we highlight where further empirical studies or specifically designed meta-analyses would be valuable to fully understand the influence of such factors on the predictive validity of the rat self-administration model for abuse liability.
Species differences
Previous reviewers of the self-administration model have suggested that the species used may be a key experimental variable that influences the outcome of studies Schuster and Thompson, 1969) . In particular, rodent abuse potential models have been considered useful but not sufficient for predicting abuse liability, since species differences in metabolic and receptor profiles, for example, may result in misleading conclusions regarding the abuse liability of some compounds (Epstein et al., 2006) . Since findings from NHP studies are considered by some to more closely reflect the human potential for abuse than any other species Mansbach et al., 2003; Weerts et al., 2007) , we contrasted findings from rat selfadministration studies with NHP studies to further understand the influence of species differences on the predictive validity of the self-administration model. Of the 71 drugs included in this review, findings from self-administration studies conducted in NHPs were available for comparison for all but five drugs (hydrocodone, oxycodone, sufentanil, varenicline and testosterone; see Tables 1-4 for findings from NHP studies).
A comparison of discrepancies between rat studies and the clinical endpoints of abuse liability with discrepancies observed between NHP studies and the same clinical endpoints (see Table 5 ) revealed only five discrepant drug cases that could be considered as 'unique' to rodent studies (that is, rat self-administration studies did not predict abuse liability, but NHP studies did). These five cases were haloperidol, imipramine, modafinil, phenylpropanolamine and hexobarbital. Considering the limited published data available for these cases, further research is required to understand whether these discrepancies truly reflect specific limitations of the rat for understanding abuse liability (that is, limitations due to species differences). It may be that experimental variables (for examples, see Sections 4.2-4.4) were not optimised for two of the discrepant cases categorised as false negatives (modafinil and hexobarbital), while the remaining three cases categorised as false positives included rat self-administration findings that were either conflicting (haloperidol) or 'equivocal' (imipramine, phenylpropanolamine), pointing to limited reinforcing effects of these drugs in the rat model.
The overall similarity between findings from rat and NHP studies identified in the current review is perhaps unsurprising, given evidence that the principal mammalian brain pathways involved in mediating the reinforcing effects of abused drugs are conserved across mammalian species (Panksepp et al., 2002) . Nevertheless, in the design of non-clinical self-administration studies, species choice should be given careful consideration. For example, where there are clear species differences in target pharmacology, and evidence suggests that the rat may not adequately reflect human pharmacology, the use of NHP may be more appropriate. But, where no strong scientific rationale for the use of a particular species exists, more pragmatic issues will invariably guide decisions regarding species choice for self-administration studies and it may be more appropriate to use the rat (for a discussion of these issues, see Section 6).
Genetic factors (strain and sex)
A variety of rat strains have been used for self-administration studies and this variable can influence the outcome of studies. For example, etonitazine was self-administered in both Wistar and Lewis rats, but not Fisher 344 rats (Carroll and Boe, 1982; Suzuki et al., 1992) . The influence of rat strain on self-administration study outcomes has also been demonstrated for the cannabinoid receptor agonist WIN 55,212-2 (Deiana et al., 2007) , ethanol (Wilson et al., 1997) , cocaine and amphetamine (Meyer et al., 2010) . These findings could reflect, in part, strain differences in drug metabolism (Sziraki et al., 2001) or neurobiology (Dalley et al., 2007) , or may simply reflect an optimisation of methodology appropriate for some strains but not others.
In addition to strain, animal sex is also likely to influence study findings. For example, phencyclidine supported the acquisition of self-administration more readily in female than male rhesus monkeys . Similarly, female rats self-administered more morphine (Alexander et al., 1978) , fentanyl (Alexander et al., Table 5 Summary of discrepancies between findings from non-clinical self-administration studies and two clinical indicators of abuse liability. Discrepancies between selfadministration studies in rats (R) and non-human primates (NHP) and one or both clinical indicators of abuse liability were classified as representing either false positives (that is, reports of self-administration in animals but absence of reports of positive subjective-effects and/or scheduling status) or false negatives (that is, absence of selfadministration in animals, but reports of positive subjective-effects and/or scheduling status (Lancaster and Spiegel, 1992 ) than male rats. The contribution of sex differences to the behavioural effects of abused substances have been well discussed elsewhere in studies using rats (Hu et al., 2004; Lynch, 2006; Lynch et al., 2000; Lynch and Carroll, 1999; Lynch and Taylor, 2004; Roth et al., 2004) , NHPs (Grant and Bennett, 2003; Newman et al., 2006; Pakarinen et al., 1999) and humans (Fattore et al., 2008) .
Relative differences in drug intake are typically observed as a function of strain and/or sex, rather than an absolute change in the ability of a drug to function as a reinforcer in one strain and/or sex but not another. Nevertheless, meta-analyses that more closely examine the influence of rat strain and/or sex on drug self-administration behaviour are warranted to enable a more in-depth understanding of the influence of these factors. This may be of greater relevance where compounds are being developed for gender-specific indications. To some extent, the influence of genetic factors can be minimized by ensuring the inclusion of an appropriate positive control (see Section 5.3). Thus, selfadministration of the positive control in a particular strain and/or sex can increase confidence in the interpretation of negative findings for a test drug when assessed under identical conditions to those used for the positive control.
Food deprivation state
Food restriction is commonly employed in self-administration studies, and typically leads to an increase in the sensitivity of the rat self-administration model for detecting drug reinforcement. Thus, chronic food restriction can facilitate the acquisition of drug selfadministration, lower the threshold reinforcing dose, increase total drug consumption and increase the effort subjects are willing to exert in order to obtain drug (Campbell and Carroll, 2001; Carroll et al., 1979) .
However, food deprivation state may markedly influence the predictive validity of the model. For example, phentermine supported self-administration in food deprived rats but not in rats given free access to food (Papasava et al., 1985) . An influence of food deprivation state on rat self-administration study outcomes has been reported for a variety of drugs including THC (Takahashi and Singer, 1980) , etonitazine , cocaine (Oei, 1983) , phencyclidine and d-amphetamine (Glick et al., 1987) , but not fenfluramine (Papasava et al., 1986) . Similar influences of food restriction have been reported in NHP self-administration studies (for example, Comer et al., 1995) and interestingly, strong relationships between eating behaviours and drug abuse have been reported in humans (see Carr, 2007 for review) .
While food deprivation may prove beneficial for detecting drug reinforcement, it is not unreasonable to propose that manipulation of this variable could increase the occurrence of false negative or false-positive findings. Further empirical studies and/or meta-analyses that more closely examine the influence of food deprivation state on drug self-administration behaviour would be of great value to understand the influence of this factor on selfadministration study outcomes. Food deprivation state should be given careful consideration, although again the inclusion of an appropriate positive control (see Section 5.3) can add confidence to findings for a test drug when assessed under identical conditions as the positive control.
Study design and drug history
Non-clinical self-administration study designs can be broadly categorised into two paradigms. In 'acquisition studies' the ability of the test drug to support the learning of a novel operant response is examined using drug-naïve animals. In 'substitution studies' the ability of the test drug to reinforce operant responding is examined in animals with prior drug self-administration experience.
Drug substitution paradigms for self-administration studies have some clear advantages in terms of the number of animals used and cost . But, perhaps the most significant advantage of substitution paradigms is that they possess greater face validity in terms of modelling the potential for drug abuse in recreational drug abusers. Substitution paradigms can also be considered more analogous to human abuse liability tests that use volunteers with histories of drug use (Carter and Griffiths, 2009 ). However, there remain important considerations regarding the design and interpretation of substitution studies in animals, which may influence predictive validity. Notably, the drug experience of the animal prior to receiving the test drug (that is, the drug history) can markedly influence subsequent responding for the test drug. For example, Hoffmeister and Schlichting (1972) reported that rhesus monkeys trained to self-administer codeine subsequently self-administered higher levels of narcotic and non-narcotic analgesics and showed less intra-individual variability than monkeys trained to self-administer cocaine. Similarly, in single substitution sessions in rhesus monkeys, responding was not observed for phencyclidine, dexoxadrol and dextrorphan when substituted for codeine, but was observed when these drugs were substituted for ketamine (Young and Woods, 1981) .
Although drug substitution designs may prove more sensitive for detecting drug reinforcement, the benefits of acquisition designs should not be overlooked. Acquisition studies allow the strictest assessment of a compounds reinforcing efficacy, in that a positive signal can only reflect drug-induced reinforcement and is immune from the influence of any previously acquired associations. However, negative findings from acquisition studies can prove difficult to interpret, since they may arise when any number of experimental variables are not appropriate or optimal for that particular drug (see Section 5.3 for further discussion).
Our review identified examples where discrepancies between findings could potentially be attributed to the study design and/or the drug history of the animals. In particular, a number of discrepancies were identified amongst different self-administration studies for the same GABAergic drug in both rats and NHPs (for example, chlordiazepoxide, diazepam and flurazepam). Although these discrepancies could reflect relatively weak reinforcing effects of these drugs or subtle methodological differences, they may also highlight the importance of the study design. For example, chlordiazepoxide supported the acquisition of self-administration in drug-naive rats (Davis et al., 1987) and maintained selfadministration in rats previously trained to self-administer ethanol, but not in previously cocaine trained rats (Falk and Tang, 1989a) . Similarly, flurazepam supported self-administration in NHPs trained to self-administer a CNS depressant, but selfadministration of flurazepam was considered equivocal in NHPs trained to self-administer a CNS stimulant (see Table 3 for references). Further empirical studies are required to fully understand and optimise the study design and/or drug history conditions required to accurately assess the abuse potential of GABAergic drugs in the rat self-administration model.
The influence of study design on the outcome of non-clinical self-administration studies is mirrored by clinical studies where the prior drug experience of human volunteers can markedly influence reports of subjective-effects. For example, both diazepam and GHB induced positive outcomes in clinical subjects who were regular users of CNS depressants, but not in drug-naïve or recreational drug users (Carter et al., 2006; Ferrara et al., 1999; Singh et al., 2001) . Similarly, nicotine produced reports of positive subjectiveeffects in smokers, but not non-smokers (Soria et al., 1996) and methylphenidate produced subjective reports of 'liking' in psychomotor stimulant users but not non-dependent light drug users at comparable doses (Heil et al., 2002; Heishman and Henningfield, 1991) .
In rats, dextromethorphan and modafinil did not support selfadministration when assessed under acquisition conditions, but both drugs are associated with abuse liability (see Table 4 for references). Similarly, the antihistamines diphenhydramine and tripelennamine either failed to support self-administration in drugnaïve rats (Fuchs and Coper, 1986) or were self-administered by only a few of the experimental animals (Jun et al., 2004) . Although diphenhydramine and tripelennamine are not controlled substances, both drugs produced reports of positive subjectiveeffects (see Table 2 for references) and the abuse of CNS active antihistamines has been recognised (Thomas et al., 2009) . Critically, while these four drugs failed to support self-administration in drugnaïve rats, all four drugs reliably supported self-administration in NHPs with prior drug experience. Thus, for the purpose of advancing our understanding of the predictive validity of the rat for abuse liability, it will be of great value to understand whether any of these drugs could support self-administration in drug experienced rats.
Improving the predictive validity of the self-administration model
Understanding relative reinforcing efficacy
The present review collated information on whether or not a drug supported self-administration in animals and whether or not a drug was associated with abuse liability in humans. In truth, this 'binary approach' represents a superficial view of abuse liability and a key area for future focus will be to understand not only if a compound is likely to possess abuse liability, but what the relative risk of abuse liability will be. Understanding the relative risk of abuse liability will require advancement of both non-clinical models of abuse potential and the clinical indicators used to assess abuse risk (for further discussion see Conway et al., 2010; Katz, 1990; Nutt et al., 2007) .
In the animal drug self-administration model, advancements in understanding the reinforcing effects of a drug relative to other comparator agents (termed, relative reinforcing efficacy) include the incorporation of more complex reinforcement schedules, such as the progressive ratio (PR) schedule (Gardner, 2000; Katz, 1990; Richardson and Roberts, 1996; Rowlett, 2000; Stafford et al., 1998) , choice procedures (Negus, 2003; Ward et al., 2005) and the application of behavioural economics to generate demand curves based on a labour-supply analysis (Hursh, 1980; Rowlett, 2000) . Two additional models developed within the sphere of addiction research may also hold promise for predicting relative risk of abuse liability. In the binge self-administration model, rats given extended access to cocaine are observed to escalate drug intake relative to rats provided with only short periods of drug access (Ahmed and Koob, 1998) . Using this model, it may be of interest to understand whether drugs that demonstrate greater propensity for abuse are also more likely to support the escalation of drug intake. Secondly, continued drug self-administration in the face of punishment (such as a mild electric shock) is considered to model one aspect of drug addiction (Deroche-Gamonet et al., 2004 ), but this model may also be useful to determine relative reinforcing efficacy. Thus, relatively weak reinforcers may fail to support drug self-administration under conditions of punishment (but see Davis, 1968 for an example where punishment may increase self-administration behavior). Considerable research is still required to fully understand whether these two models have utility in abuse liability research. Traditionally, the assessment of abuse potential, as opposed to addiction potential has been considered sufficient as a preclinical contribution to the scheduling recommendation, based on an assumed relationship between abuse potential and addictive potential. While the use of models more closely aligned to addiction potential may be valuable in differentiating between drugs, their use should be clearly justified and based on testing clear hypotheses.
For some of the false-positive findings identified in the present review, an assessment of relative reinforcing efficacy in animals offered a more accurate reflection of abuse liability risk in humans. For example, tramadol maintained self-administration in both rats and NHPs, but was identified as a weak reinforcer relative to drugs with known abuse liability when examined under a PR schedule of reinforcement Yanagita, 1978) . These findings are entirely consistent with clinical studies indicating that tramadol does possess abuse liability, although the incidence of tramadol abuse is far lower than for typical opioid analgesics (Epstein et al., 2006) . Similarly, varenicline maintained self-administration in rats, but is not associated with abuse liability in humans (McColl et al., 2008) . However, when assessed using a PR schedule in the rat self-administration model, varenicline was identified as a weak reinforcer relative to nicotine (Rollema et al., 2007) .
It is likely that more accurate predictions of abuse liability may have been made for other false positives identified in our review, had assessments of relative reinforcing efficacy been employed. For example, the adrenergic drugs clonidine and ephedrine were selfadministered in rats and NHPs (see Table 2 for references) while clinically, these drugs are identified as weak reinforcers relative to drugs with high risk of abuse liability (Chait, 1994) . Further studies of relative reinforcing efficacy will be critical for understanding the methodological variables that influence these assessments, and how findings from these approaches translate to relative abuse liability risk in humans.
Pharmacokinetic modelling and adverse event profiles
A unique feature of the self-administration model is that the total drug dose administered is dependent on the behaviour of the animal. This is in stark contrast to the majority of behavioural pharmacology and safety studies, where the effects of an experimenter defined dose are assessed. By assessing the pattern of drug infusions from self-administration studies and applying in-silico pharmacokinetic (PK) modelling methods to these data, it may be possible to understand drug exposure levels that are optimal for maintaining reinforcement in animals (Crespo et al., 2006; Lau and Sun, 2002; Tsibulsky and Norman, 2005) .
Although still in its infancy, the potential strength of PK modelling for self-administration studies lies in understanding the relationship between drug exposure levels (or drug target onset and offset rates) necessary for maintaining drug reinforcement in animals relative to clinical efficacious dose levels and, critically, clinical dose levels associated with side effects that may limit abuse liability (for example, nausea or seizures). With this information, abuse potential researchers may be able to better predict and minimize the likelihood of abuse.
Based on the studies included in the present review, we can only speculate about the advantages that PK modelling together with the integration of adverse event profiles could offer for predicting risk of abuse liability. However, we propose that the abuse liability of a number of drugs may have been better predicted by taking this approach. First, bupropion supported self-administration in rats and NHPs, but is not associated with abuse liability in humans. Although the reason for this discrepancy is not fully understood (but see Tella et al., 1997) , one possible explanation is that the intravenous route of administration in non-clinical studies facilitated a rate of drug onset and drug exposure levels necessary to support drug reinforcement in animals, while clinically bupropion is marketed as a slow release oral formulation that is likely to preclude such effects in humans (Dwoskin et al., 2006; Stathis et al., 1995) . Further, attempts to misuse bupropion via nasal insufflation have been reported to result in seizures, which may further limit the abuse of this drug (Kim and Steinhart, 2010) . Second, both apomorphine and bromocriptine were self-administered in rats and NHPs, but neither drug is associated with abuse liability. Critically, both drugs are associated with adverse reactions in humans that may limit their potential for abuse (LeWitt et al., 2009; Preston et al., 1992a ). Third, varenicline was self-administered in rats but is not associated with abuse liability in humans. Findings from a clinical abuse potential study demonstrated that although varenicline produced a 'drug high' in non-smokers at drug levels that exceeded efficacious doses, these reports also corresponded with reports of nausea. Thus, reports of a 'drug high' following varenicline administration were unlikely to be positive in nature and these findings likely underwrite the lack of varenicline abuse (McColl et al., 2008) . Finally, although tramadol was self-administered in rats and NHPs, an appreciation of tramadol's complex pharmacological and metabolic profile provides a substantial account for it's limited abuse liability (see O'Connor and Mead, 2010 for further discussion).
Selecting appropriate control substances
Without appropriate control substances, negative findings from drug self-administration studies are difficult to interpret, since they may occur when any number of experimental variables (including response-contingencies, infusion rates, drug-paired environmental stimuli, dose, schedule of reinforcement, daily schedule of drug access and route of drug administration) are not appropriate or optimal for the particular test drug. To overcome these concerns, the selection of appropriate positive and negative controls is critical for all self-administration studies.
A positive control should clearly support robust drug selfadministration in animals and as such is often used as the training drug in substitution based paradigms. But, there are a number of other considerations that should be taken into account when selecting an appropriate control substance and which may improve the predictive validity of the model. Ideally, the positive control should be selected from the same pharmacological class as the test drug, since the conditions required for robust self-administration behaviour can differ across drug classes. Where an appropriate positive control cannot be identified based on pharmacology (for example, where the test drug has a novel or unknown mechanism of action), a positive control that produces a similar behavioural profile as the test drug may serve as the most appropriate comparator agent. Where neither pharmacology nor the behavioural profile of the test drug can be used to select an appropriate positive control, scheduled drugs that share the intended clinical indication as the test substance may provide useful comparator agents.
Other criteria for selecting positive control agents may take into account the metabolic profile of the test agent. For example, remifentanil, rather than morphine, may offer a more appropriate positive control for a novel opioid related drug with a short duration of action. Control substances may also be chosen to help differentiate between the test drug and drugs in different scheduling levels or to provide a direct comparator to control substances used in clinical abuse potential studies. Finally, unscheduled drugs or drugs that are not abused, but yet give positive signals (for example, bupropion) may be included to provide context, since such drugs can highlight the limitations, sensitivity or principles of the self-administration model.
Equally important as the inclusion of an appropriate positive control is the inclusion of a negative control (that is, a substance devoid of abuse liability) which can be used to define a negative signal under the particular test conditions. Typically, the vehicle of the test substance provides the most appropriate and convenient negative control. A drug that is devoid of abuse liability, but which shares a similar mechanism of action and/or is marketed for the same clinical indication as the test drug may also serve as an informative negative control substance.
Discussion
This report provides an overview of findings from selfadministration studies conducted in rats with a view to understanding the predictive validity of the rat self-administration model for assessing the risk of abuse liability. Our findings show that outcomes from rat self-administration studies, which encompass a broad range of drug classes, show high concordance with two clinical indicators of abuse liability, namely reports of positive subjective-effects (that is, 'liking', 'euphoria' and/or 'high') and drug scheduling status. These findings lend support to previous comments that the self-administration model represents a critical component of drug abuse liability assessments Balster, 1991; Carter and Griffiths, 2009) .
Understanding the predictive strengths and limitations of the self-administration model depends heavily upon the number of published studies available for each drug and, in turn, the number of drugs that have been assessed within a particular drug class. While it is not possible to state the minimum number of studies required to fully understand the predictive validity of the model for any given drug or drug class (one well designed study may be more convincing than three poorly conceived studies), confidence in the model will invariably increase in line with the number of published studies that use a variety of methodologies. Our review identified a number of specific drug cases where further studies would be beneficial to fully understand the predictive validity of the rat self-administration model (for example, haloperidol, hexobarbital, and modafinil). Similarly, studies of additional drugs are required to fully understand the strengths and limitations of the rat model for use in assessing the abuse liability of certain drug classes (in particular, cannabinoids, steroids and adenosinergic drugs).
Assessing the predictive validity of non-clinical models also depends heavily on the strength of the chosen clinical endpoint to which the model is compared (see Katz (1990) for further discussion of this issue). Thus, one of the major challenges for this review was to select reliable indicators of abuse liability. As highlighted in the following discussion, a number of limitations associated with the use of subjective-effects studies and drug scheduling status for indicating abuse liability are acknowledged and, in some cases, these limitations may have contributed to discrepancies identified between non-clinical studies and the clinical or regulatory indicators of abuse liability.
With respect to reports of subjective-effects, restricting this measure to reports of positive effects (that is, 'liking', 'euphoria' and/or 'high') precluded incorporation of other subjective-effects, such as dysphoria or nausea, which may limit the overall abuse liability of a compound. For example, although levallorphan engendered reports of positive subject effects, it produced overall changes in subjective-effects that were quite distinct from those of morphine and other narcotic analgesics (Jasinski et al., 1967) . Second, it is recognised that different scales of positive subjective-effects may not directly correlate and can have differing sensitivities across different drug classes. For example, non-drug abusing volunteers reported significant 'drug liking', but not a 'drug high' following administration of morphine (Zacny and Gutierrez, 2003) . Third, it has been argued that drug reinforcement and subjective responses in humans are dissociable phenomena (Henningfield et al., 1987; Johanson and Uhlenhuth, 1981; Lamb et al., 1991; Martinez et al., 2004) , thus reports of positive subjective-effects may have limited use in providing a direct clinical comparison to non-clinical studies that examine drug reinforcement.
Drug scheduling status was chosen as a second clinical indicator of abuse liability, since it could potentially offer a more comprehensive reflection of 'real-world' abuse liability than reports of positive subjective-effects alone. However, a number of drugs with recognised abuse liability are not currently listed as controlled substances (most notably, nicotine and ethanol but also see propofol, dextromethorphan and diphenhydramine). Consequently, findings from some non-clinical studies that were identified as discrepant with respect to the drug scheduling status could readily be attributed to inconsistencies between the scheduling status and published clinical reports of drug abuse.
To overcome the limitations associated with reports of subjective-effects and drug scheduling status, one must look to other clinical endpoints of abuse liability. Recent reviewers have noted that findings from human self-administration studies are more predictive of abuse liability than reports of subjective-effects alone Haney and Spealman, 2008) . In conducting our review, we found that studies of drug selfadministration in humans were limited to only a few of the drugs that were included in this review. If this model is used more routinely and consistently in the clinic, it may serve as a valuable clinical indicator of abuse liability against which the predictive validity of non-clinical self-administration studies can be compared.
Our current review identified relatively few cases where discrepancies between rat self-administration studies and the clinical endpoints of abuse liability were not mirrored by selfadministration studies conducted using NHPs. Thus, where no strong scientific rational for the use of a particular species exist, more pragmatic issues will invariably guide decisions regarding species choice for self-administration studies. Rats and NHPs each have their own benefits which must be considered against the aims of the study. A clear benefit for using NHPs is that catheter patency can be maintained for a longer period of time than is typical in the rat, permitting the use of more complex schedules of reinforcement and allowing for complete within-subject designs. In addition, NHPs often have self-administration experience that encompasses a variety of drug classes, which may offer greater validity for modelling the potential for drug misuse in human poly-drug abusers. However, rats offer a number of distinct advantages over NHPs in terms of cost, care, and availability. Rat self-administration studies can therefore be used early in drug development to enable critical decisions on whether to continue investigating a novel compound or target. Further, much of non-clinical drug discovery and development is performed in the rat, thus facilitating the design of abuse potential studies with the added knowledge of efficacious doses, pharmacodynamic and metabolic profiles and adverse drug effects. Finally, there are ethical considerations regarding the selection of species for animal experimentation. The selection of species for use in animal research with the lowest degree of neurophysiologic sensitivity, termed 'phylogenetic reduction', is in line with European regulations (European Union (2010) Directive 2010/63/EU) and UK national legislation, which gives special protection to the use of cats, dogs and primates in animal research (UK Government, Animals (Scientific Procedures) Act, 1986). Phylogenetic reduction is also consistent with recent regulatory guidance on the nonclinical investigation of dependence potential, stating that rodents or other non-primate models deserve preference above primate models where available, provided the chosen species is appropriate for the active substance tested and the model is validated and technically feasible (EMEA, 2006; ICHM3 (R2), 2010) .
In summary, the current review confirms the rat selfadministration model as a valuable tool for use in assessments of abuse liability. Given the number of experimental variables that can influence study outcomes, the design of rat self-administration studies will be critical for determining the predictive strength of the model when used in assessments of abuse liability for novel CNS active drugs. A number of exciting opportunities exist to enhance the predictive validity of the self-administration model, including the development of robust methods to assess relative reinforcing efficacy and using PK modelling methods to understand the relationship between drug dose levels necessary for supporting drug reinforcement relative to dose levels associated with adverse clinical events, which may serve to limit abuse liability. However, one must remember that the drug self-administration model measures only one of many factors that can contribute to abuse liability (that is, drug reinforcement). Thus 'real world' assessments of abuse liability that integrate data from a variety of non-clinical and clinical abuse potential models will invariably provide a more accurate assessment of abuse liability risk than data from any one abuse potential model Carter and Griffiths, 2009; Haney and Spealman, 2008; Mansbach et al., 2003; ). An ongoing challenge for abuse potential research will be to continue developing and refining non-clinical and clinical models of abuse potential, and determine how best to incorporate data from multiple sources in order to maximize the predictive strength of abuse liability assessments and thereby minimize risk to public health.
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